Catalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Rusfertide (Hepcidin Mimetic) in Polycythemia Vera. The expected timing is based on the latest available company guidance and may change.
07/30/26:- Ph3 benefits reiterated; Priority Review continues; U.S. launch expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.